In this article we will be analyzing Crispr Therapeutics AG. We will be looking over the current market data to assess wether or not it is a good investment. To get started, the stock opened this morning at $128.42 and has moved $-0.849999999999994 from yesterday’s closing price of $127.1. The high for today is $130.4595 and the low is $125.835. A great indicator of where a stock is trending is by looking at it’s 52-week high/low. This is a technical indicator used by some traders and investors who view these figures as an important factor in the analysis of a stock’s current value and as a predictor of its future price movement. The 52-week high for Crispr Therapeutics AG is $220.2 and the low is $76.71. The volume (the number of shares traded in a stock or contracts traded in futures or options.) is 933495. Now that we know where Crispr Therapeutics AG stands in price and volume, let’s learn more about the future of the company.
Forecast & Beta
As an investor, you can get an idea of where the stock is trending by the forecast and beta. Beta is calculated using regression analysis. A beta of 1 indicates that the security’s price tends to move with the market. A beta greater than 1 indicates that the security’s price tends to be more volatile than the market. A beta of less than 1 means it tends to be less volatile than the market. Crispr Therapeutics AG has a beta of 2.26258. Knowing all of this, we project that Crispr Therapeutics AG will have a price of $168.3 in 12-months compared to it’s current price of $126.25 ($-333.21 difference). We can also take a look at the comapany’s marketcap. Marketcap is important because it allows investors to understand the relative size of one company versus another. Market cap measures what a company is worth on the open market, as well as the market’s perception of its prospects, because it reflects what investors are willing to pay for its stock. Crispr Therapeutics AG has a marketcap of $10270480000.